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A B S T R A C T
Chronic kidney disease (CKD) is a common medical condition of ageing cats. In most cases the under-
lying aetiology is unknown, but themost frequently reported pathological diagnosis is renal tubulointerstitial
fibrosis. Renal fibrosis, characterised by extensive accumulation of extra-cellular matrix within the in-
terstitium, is thought to be the final common pathway for all kidney diseases and is the pathological
lesion best correlated with function in both humans and cats. As a convergent pathway, renal fibrosis
provides an ideal target for the treatment of CKD and knowledge of the underlying fibrotic process is
essential for the future development of novel therapies. There are many mediators and mechanisms of
renal fibrosis reported in the literature, of which only a few have been investigated in the cat. This article
reviews the process of renal fibrosis and discusses the most commonly cited mediators and mecha-
nisms of progressive renal injury, with particular focus on the potential significance to feline CKD.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
Introduction
Chronic kidney disease (CKD) is defined as the presence of struc-
tural or functional abnormalities of one or both kidneys that have
been present for an extended period of time. CKD is common in cats,
one study reporting that 12% of all cats necropsied over a period
of 3 years were suffering from the condition (Taugner et al., 1996).
The prevalence of CKD also increases with age, with reported prev-
alence rates of 28% in cats over 12 years old (Bartlett et al., 2010)
and 31% in cats over 15 years old (Lulich et al., 1992).
The aetiology of feline CKD is heterogeneous and includes spe-
cific disease processes which initiate renal damage or dysfunction,
such as polycystic kidney disease, renal amyloidosis, renal dyspla-
sia and renal lymphoma (Reynolds and Lefebvre, 2013). However in
themajority of catswith CKD no inciting cause is identified. One study
of a referral population found pathological lesions of a specific renal
disease in 50% of cases (DiBartola et al., 1987), another in 33% of cases
(Minkus et al., 1994). A recent study with a large population from
first opinion practices identified specific renal lesions in only 16% of
cats (Chakrabarti et al., 2013). Themajority of cats with CKD are found
to have non-specific renal lesions and the predominant morpholog-
ical diagnosis in these cases is chronic tubulointerstitial inflammation
and fibrosis (DiBartola et al., 1987; Chakrabarti et al., 2013).
The underlying aetiology of CKD in the majority of cats, where
chronic tubulointerstitial fibrosis is present, is not understood.
Various factors which may contribute to renal damage have been
proposed, including diet (Hughes et al., 2002), vaccination (Lappin
et al., 2006), and ageing (Lawler et al., 2006). Regardless of the ae-
tiology, the progressive nature of renal fibrosis results in deterioration
of renal function independent of the initial renal insult. Renal
tubulointerstitial fibrosis is recognised as the final common pathway
for all kidney diseases in human patients regardless of aetiology
(Prunotto et al., 2011) and is the pathological lesion best corre-
lated with renal function in both humans (Risdon et al., 1968; Nath,
1992) and cats (Yabuki et al., 2010; Chakrabarti et al., 2013).
Despite ongoing research there is currently no effective treatment
that significantly slows the progression of renal fibrosis in humans or
in cats. Therefore,much attention is directed at identifying factorswhich
influence or drive the progression of fibrosis in order to identify po-
tential therapeutic targets. The aim of this article is to provide a review
of the renal fibrotic process and evaluate previous research published
on mediators and mechanisms of renal fibrosis, with particular focus
on those investigated in cats, in order to provide updated information
for veterinary clinicians and pathologists.
Renal fibrosis
In most cases of tissue damage, injured cells are replaced by cells
of the same type and/or fibrous tissue after the resolution of the
inflammatory response. The kidney has an intrinsic capacity for
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self-repair after ischaemic or toxic insults that result in cell death
and can potentially recover completely after sustaining acute injury.
This repair occurs primarily through epithelial cell proliferation, and
it appears that an intact basement membrane plays an important
role by providing a scaffold along which regenerating epithelial cells
can spread and migrate (Toback, 1992; Bonventre, 2003). Healing
via focal fibrotic scarring is also seen secondary to severe paren-
chymal injury, for instance in pyelonephritis or infarction, and serves
to maintain tissue integrity. Whilst fibrosis is a normal sequel of
injury, it is thought that in CKD the normal wound healing re-
sponse fails to terminate (Liu, 2006;Wynn, 2010). Although the exact
mechanisms underlying this dysregulation are unclear, the result
is an excessive, inexorable fibrogenic response and the expansion
of the extra-cellular matrix (ECM) gradually destroys normal tissue
structure (Eddy, 1996). The histopathology of renal fibrosis fea-
tures excessive accumulation of ECM proteins within the
tubulointerstitial space and is accompanied by loss of the renal mi-
crovasculature, infiltration of mononuclear cells, tubular atrophy and
dilation (Fig. 1). The aberrant extracellular matrix is composed of
normal matrix proteins and proteoglycans as well as other matrix
proteins normally restricted to tubular basement membranes, such
as collagen IV and laminin (Vleming et al., 1995; Eddy, 1996).
In the normal kidney, interstitial fibroblasts play a crucial role
in ECM homeostasis via their dual roles in the synthesis of ECM and
production of ECM degrading proteases (Strutz and Zeisberg, 2006).
In fibrogenesis, these cells are believed to become activated and
undergo a phenotypic change to become myofibroblasts. The in-
duction and proliferation of myofibroblasts is probably a crucial event
in the initiation and progression of renal fibrosis. Myofibroblasts
possess qualities of both fibroblasts and smooth muscle cells and
are considered the dominant ECM producing cells in organ fibro-
sis (Prunotto et al., 2011; Lebleu et al., 2013). It is not possible to
differentiate these cells from fibroblasts via light microscopy and
they are characterised by their expression of alpha smooth muscle
actin (α-SMA) and vimentin. Both vimentin and α-SMA expres-
sion increase within the kidney in naturally occurring feline CKD
and the expression of these cellular markers correlates with in-
creasing plasma creatinine concentration and kidney fibronectin
deposition (Sawashima et al., 2000; Yabuki et al., 2010).
The precise origin of myofibroblasts has historically been con-
troversial, and several cell types as well as resident fibroblasts are
known to undergo phenotypic changes to ECM producing cells in
renal fibrosis, including tubular epithelial cells, circulating fibrocytes,
vascular pericytes, endothelial cells and glomerular podocytes (Kim
et al., 2013). The relative contribution of these cellular types to the
myofibroblast pool is the focus of ongoing investigation. One recent
comprehensive analysis examining the relative contribution of
various cell types to the myofibroblast lineage, using mice with ex-
perimentally induced obstructive renal disease, found that 50% of
the population arose from proliferation of resident fibroblasts whilst
the remainder differentiated from bone marrow derived cells (35%),
endothelial cells (10%) and epithelial cells (5%) (Lebleu et al., 2013).
Myofibroblast induction, proliferation and ECM production are
regulated by a number of local and circulating factors. These include
paracrine or autocrine growth factors, direct interaction with
leucocytes/macrophages, and environmental stimuli such as hypoxia
and hyperglycaemia (Qi et al., 2006). Recent studies have also
emphasised the importance of renal tubular epithelial cell damage
and altered epithelial–mesenchymal cell signalling in the activa-
tion of renal fibroblasts towards the myofibroblast type in CKD
(Prunotto et al., 2012; Moll et al., 2013).
Pro-fibrotic mediators
Transforming growth factor beta (TGF-β)
The cytokine TGF-β is potentially the most important pro-
fibrotic mediator responsible for myofibroblast activation, appearing
to be a convergent pathway that integrates the effects of many other
fibrogenic factors (Liu, 2006; Farris and Colvin, 2012). TGF-β1 is the
most abundant isoform and is synthesised by all cell types of the
kidney, with epithelial cells demonstrated to be the main source
in experimentally induced disease (Fukuda et al., 2001; Wu et al.,
2013). TGF-β is secreted as a latent precursor andmust undergo pro-
teolytic cleavage in order for the active form of the cytokine to be
liberated, which may be initiated directly by a variety of mol-
ecules including plasmin and reactive oxygen species (Annes et al.,
2003). Once activated, TGF-β exerts its subsequent effects by binding
to the TGF-β receptor II and regulating the transcription of target
genes (Wang et al., 2005). Production of TGF-β has been demon-
strated to be induced by a variety of stimuli, including the renin–
angiotensin–aldosterone system (Wolf, 2006), hypoxia (Orphanides
et al., 1997), proteinuria (Eddy and Giachelli, 1995), increased single
nephron glomerular filtration rate (Rohatgi and Flores, 2010) and
oxidative stress (Shin et al., 2008).
TGF-β is upregulated in nearly all mammalian chronic kidney
diseases, and evidence from rodent models supports the hypoth-
esis that TGF-β signalling is central to the induction of kidney disease.
Mice overexpressing TGF-β develop interstitial fibrosis (Koesters et al.,
2010) and downstream disruption of the TGF-β signalling pathway
has been demonstrated to ameliorate renal fibrosis (Sato et al., 2003).
The profibrotic effects of TGF-β include inducing the formation of
myofibroblasts from various cell types in vitro, including fibro-
blasts (Serini et al., 1998), pericytes (Wu et al., 2013) and potentially
also endothelial cells (He et al., 2013), although the relative signif-
icance of these findings in vivo is controversial. It directly stimulates
transcription of ECM genes in many renal cells, including tubular,
endothelial and mesangial cells (Border and Noble, 1993) and also
decreasesmatrix degradation (Edwards et al., 1987; Krag et al., 2005).
TGF-β1 signalling in tubular epithelial cells alone, independent of
myofibroblasts, is sufficient to cause tubular injury, apoptosis and
accumulation of inflammatory cells (Gentle et al., 2013). As well as
direct effects, TGF-β also acts to stimulate cell proliferation and ECM
accumulation through downstream activation of the pro-fibrotic
cytokine connective tissue growth factor (CTGF) (Grotendorst, 1997).
TFG-β (normalised to urinary creatinine) has been shown to be
present in increased concentrations in the urine of cats with
Fig. 1. Photomicrograph illustrating severe cortical interstitial fibrosis and inflam-
mation in the kidney of a cat with CKD. Periodic acid-Schiff and haematoxylin.
Reprinted with permission from Veterinary Pathology, SAGE publications.
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naturally occurring CKD. One study found a significant increase in
urine TGF-β1:urine creatinine ratio (TGF-β1:UCrR) in a group of 23
cats with CKD in comparison to a group of 13 healthy controls, whilst
documenting no difference in serum TGF-β1 concentrations (Arata
et al., 2005). Another study comparing 18 healthy cats to 26 with
CKD also demonstrated an increased TGFβ1:UCrR in cats with CKD,
and a positive correlation between TGF-β1:UCrR and serum cre-
atinine (Habenicht et al., 2013). These preliminary results suggest
urinary TGF-β1 may be useful as a biomarker of renal injury in CKD
and a potential tool for assessing response to therapeutic interven-
tions. However, a major disadvantage of feline studies to date is the
lack of concomitant histopathology with which to correlate these
findings. Furthermore, the relative value of the different forms of
TGF-β1 measured in feline urine and/or serum as biomarkers of
active renal pathology warrants further study.
Components of the renin–angiotensin–aldosterone system
The renin–angiotensin–aldosterone system (RAAS) is an endo-
crine pathway that plays an integral role in the homeostatic control
of arterial pressure, tissue perfusion and extracellular volume (Atlas,
2007) (Fig. 2). The RAAS is upregulated early in CKD (Siragy and
Carey, 2010) and plasma renin, aldosterone and angiotensins I and
II have been demonstrated to be increased in the circulation of cats
with experimentally induced CKD (Watanabe and Mishina, 2007).
Both systemic and intrarenal RAAS exist, and assessment of the sys-
temic RAAS alone does not necessarily indicate the state of the RAAS
system in the kidney. Angiotensin II in particular may be present
in much higher concentrations within the kidney than in the cir-
culation (Kobori et al., 2007).
The RAAS is a mediator of progressive renal injury via increas-
ing glomerular pressure and the subsequent filtration of plasma
protein, but its components also have direct fibroproliferative effects.
Angiotensin II, the primary active product of the RAAS, is believed
to be the most important via upregulation of TGF-β signalling and
pro-inflammatory gene transcription (Ruster and Wolf, 2011). As
well as TGF-β, angiotensin II also has the potential to induce a variety
of other pro-inflammatory and pro-fibrotic mediators including CTGF
and endothelin 1 (Yokoi et al., 2001; Wolf et al., 2002). Aldoste-
rone and renin are also implicated as effectors of fibrogenesis by
increasing TGF-β expression and production respectively (Sun et al.,
2000; Juknevicius et al., 2004; Huang et al., 2006). Aldosterone is
also believed to have TGF-β independent effects via stimulating pro-
duction of CTGF (Han et al., 2006).
Suppression of the RAAS via inhibition of angiotensin convert-
ing enzyme (ACE) has been demonstrated to ameliorate or halt renal
fibrosis in several models of CKD (Ishidoya et al., 1996; Garber et al.,
1998; Mizuno et al., 1998), although conflicting reports exist (Turan
et al., 2003). Administration of ACE inhibitors to human patients with
a range of kidney diseases delays progression of CKD, indepen-
dent of their anti-hypertensive action (Maschio et al., 1996), but this
effect has not yet been demonstrated in cats. In clinical trials of ACE
inhibitors in cats with CKD, those receiving benazepril showed a
significant reduction in proteinuria, but to date, no significant sur-
vival benefit (King et al, 2006; Mizutani et al., 2006; Watanabe and
Mishina, 2007). One study investigating the relationship between
the intra-renal expression of renin and angiotensin II and renal his-
topathology in cats found no relationship between their expression
and tubulointerstitial fibrosis, although there were only 13 cats en-
rolled in this study (Mitani et al., 2013). The same study documented
a positive correlation between interstitial angiotensin II expres-
sion and fibrosis in dogs, and thus it is possible that the intra-
renal RAAS is not as significant a mediator of interstitial fibrosis in
cats as it appears to be in other species.
Transglutaminase 2
Transglutaminase 2 (TG-2) is an ubiquitously expressed member
of the transglutaminase family of calcium dependent cross-linking
enzymes with important enzymatic and non-enzymatic functions
in the extracellular matrix (Belkin, 2011). The transamidase activ-
ity of TG-2 plays a role in extracellular matrix stabilisation by cross-
linking extracellular matrix proteins (Shweke et al., 2008; Iismaa
et al., 2009). This leads to increased ECM deposition and resis-
tance to ECM breakdown via proteolytic enzymes (Johnson et al.,
1999). In addition to its direct enzymatic effects TG-2 is involved
in cross-linking TGF-β1 to the ECM (Annes et al., 2003) and may
contribute to tissue fibrosis via activation of TGF-β1 (Shweke et al.,
2008), as well as stimulating pro-inflammatory signalling (Kim et al.,
2010).
TG-2 has been linked to a variety of fibrotic conditions affect-
ing the liver, lung, heart and kidney (Iismaa et al., 2009).
Experimental administration of TG-2 inhibitors to rodent models
of kidney disease decreases the severity of fibrosis, implicating TG-2
as an active player in the progression of fibrosis in CKD (Johnson
et al., 2007; Huang et al., 2009). A strong association between TG-2
expression and renal fibrosis has been observed in rodent models
(Johnson et al., 1999), humans (Johnson, 2003) and recently also
Fig. 2. The renin–angiotensin–aldosterone system.
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in cats (Sánchez-Lara et al., 2013). In addition to histopathological
changes, extracellular TG-2 activity was also positively correlated
with plasma creatinine, urea and phosphate in cats in this study.
This dual correlation of TG-2 with histopathological evidence of fi-
brosis and biochemical markers of disease severity suggests it may
be an ideal target for further investigation and a potential future
therapeutic target.
Endothelin 1
Endothelin 1 (ET-1) is a peptide produced in the heart, kidney,
central nervous system and posterior pituitary gland with varied
physiological roles throughout the body. Within the kidney it is re-
leased in response to activation of the RAAS (Kohno et al., 1992),
hypoxia (Hughes et al., 1996) and other pro-fibrotic mediators such
as TGF-β (Schnermann et al., 1996). ET-1 acts as a potent vasocon-
strictor but also has a considerable pro-fibrotic effect. Over-
expression of ET-1 results in development of interstitial fibrosis in
transgenic mice (Hocher et al., 1997) and increased renal ET-1 ex-
pression has been demonstrated in human renal disease (Duan et al.,
1999; Nakamura et al., 2000) as well as experimental models of
kidney disease (Lebel et al., 2006). Pharmacological antagonism of
the ET-1 receptor is known to attenuate fibrosis in rats with exper-
imentally induced kidney disease (Benigni et al., 1993; Ebihara et al.,
1997).
An increase in ET-1 mRNA expression in biopsied renal tissue
has been reported in one study of cats affected by renal failure
(Uchide and Saida, 2006). Conversely, in one recent analysis, plasma
and urinary ET-1 concentrations were not associated with plasma
creatinine concentration and tubular ET-1 expression was not as-
sociated with fibrosis (Chakrabarti, 2012). Total ET-1 expressionmay
however be unrepresentative of this peptide’s true role in CKD. ET
receptors have been found to be upregulated in experimentally
induced acute kidney injury (Roubert et al., 1994), as well as in
human patients with polycystic kidney disease (Ong et al., 2003),
and it is possible that it is an increased sensitivity to ET-1 that leads
to pathological effects.
Factors involved in the progression of renal fibrosis
The mechanisms behind continued and progressive fibrotic
change in CKD are not completely understood. It is thought that the
intra-renal environment in CKD is significantly pro-fibrotic, leading
to continued production of pro-inflammatory and pro-fibrotic
cytokines and the perpetuation of thewound healing response rather
than its resolution. The factors with the most influence on main-
taining this state and which have undergone the most investigation
to date are believed to be proteinuria, chronic inflammation, hypoxia,
ageing and hyperphosphataemia.
Proteinuria
The classical ‘hyperfiltration theory’ postulates that as single
nephron glomerular filtration rate increases in proportion to the
amount of renal tissue lost, plasma protein filtration increases and
subsequent glomerular and tubular damage occurs, triggering further
fibrosis and creating a vicious cycle (Hostetter et al., 1981). It is be-
lieved that excess protein within the glomerular filtrate may have
intrinsic renal toxicity due to increased uptake by tubular cells and
accumulation of abnormal amounts of protein within the intersti-
tium. Protein overload has been associated with proximal tubular
cell apoptosis in experimentally induced renal disease (Tejera et al.,
2004) and proximal tubular cells subjected to protein overload
upregulate genes encoding for pro-inflammatory and pro-fibrotic
mediators in vitro and in vivo (Eddy and Giachelli, 1995; Zoja et al.,
1999; Nakajima et al., 2002). These factors cause increased
infiltration of leukocytes in the protein-overloaded areas and chronic
inflammation results (Abbate et al., 1998). Proteinuria has been sug-
gested to be associated with increased ET-1 (Vlachojannis et al.,
2002), TGF-β (Eddy and Giachelli, 1995) and ACE expression (Largo
et al., 1999). Tubular protein overload is also believed to cause ep-
ithelial to mesenchymal transition of proximal tubular cells to
myofibroblasts, thus contributing directly to the increase in ECM
producing cells that occurs in CKD (although this is of debateable
significance) (Abbate et al., 2002).
Proteinuria is an established negative prognostic factor in feline
CKD. Urine protein to creatinine ratio (UPC) is correlatedwith plasma
creatinine concentration and independently associated with shorter
survival times (Syme et al., 2006). In one study evaluating predic-
tors of the development of azotaemia in cats, proteinuria at
presentation was significantly associated with the development of
azotaemia and alongside creatinine was the only significant pre-
dictor in a multivariable analysis (Jepson et al., 2009). UPC has also
been shown to be a significant and independent risk factor for a >25%
increase in plasma creatinine concentration within 12 months of
diagnosis of CKD (Chakrabarti et al., 2012a) and to be positively cor-
relatedwith post-mortem interstitial fibrosis score (Chakrabarti et al.,
2013). Despite these associations, it is not yet possible to infer a
causal role for proteinuria in feline CKD and renal fibrosis as these
findings may just reflect decreased tubular uptake capacity in dis-
eased kidneys. It is also possible that glomerular disease, which
proteinuria is characteristically associated with, represents a more
progressive form of CKD and is itself linked with increased
fibrosis.
Inflammation
Tubulointerstitial infiltration of lymphocytes and macrophages
is an early feature of CKD and may be induced by proteinuria, re-
active oxygen species generation and upregulation of angiotensin
II (Rodriguez-Iturbe et al., 2001). Regardless of the initial cause,
chronic renal inflammation is believed to play a critical role in the
pathophysiology of CKD and the perpetuation of renal fibrosis
(Rodriguez-Iturbe and Garcia Garcia, 2010). Depletion of inflam-
matory cells, such as macrophages and T-cells, has been
demonstrated to ameliorate progression of tubulointerstitial fibro-
sis in rodent models of kidney disease (Ko et al., 2008) (Tapmeier
et al., 2010). A variety of agents which interfere with the inflam-
matory process have also demonstrated the ability to prevent
inflammatory cell infiltration and progression of renal fibrosis in
experimental models, including the immunosuppressive drug
mycophenolate mofetil (Romero et al., 1999), chemokine receptor
CCR1 antagonists (Vielhauer et al., 2004), and inhibitors of the pro-
inflammatory NF-κB pathway (Tamada et al., 2003).
Chronic inflammation sustains the production of pro-fibrotic
growth factors and chemokines from activated epithelial and en-
dothelial cells, as well as infiltrating leukocytes. Macrophages have
been hypothesised to promote fibrogenesis via TGF-β signalling (Ko
et al., 2008) but have also been demonstrated to switch from a pro-
inflammatory to a suppressive phenotype after initial kidney damage
(Lee et al., 2011), and their true role in renal injury and disease is
likely to be complex. T-cells are believed to modulate myofibroblast
activation, either via direct effects on resident fibroblasts or via in-
ducing macrophages/tubular cells to produce profibrotic cytokines/
growth factors (Nikolic-Paterson, 2010). Inflammatory cells are also
able to differentiate into myofibroblasts and may contribute direct-
ly to ECM accumulation via this pathway (Jabs et al., 2005).
In cats, tubulointerstitial fibrosis is associated with infiltration
of lymphocytes and plasma cells (DiBartola et al., 1987) and one
recent study found a moderate correlation between the degree of
inflammation and tubulointersitial fibrosis in feline CKD (Chakrabarti
et al., 2013). The chemokine IL-8, a neutrophil chemotactic factor
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which is released by leukocytes and endothelial cells in response
to inflammation, has also been shown to be present in increased
concentrations in the urine of cats with CKD (Habenicht et al., 2013).
Hypoxia
Chronic hypoxia of the renal tubulointerstitium has been
hypothesised to be the final common pathway by which CKD pro-
gresses to end stage renal disease (Mimura and Nangaku, 2010). This
is supported by evidence from experimental models of CKD where
tubular hypoxia has been demonstrated to precede histopathologi-
cal evidence of kidney damage, suggesting a causal relationship
(Manotham et al., 2004).
Although the kidney receives 25% of cardiac output, far in excess
of metabolic requirements, it is intrinsically susceptible to hypoxia
due to the arteriovenous shunting of oxygen which results in the
extraction of no more than 10% of the oxygen delivered by the renal
artery (Evans et al., 2008). The renal cortex is perfused at a sub-
stantially greater rate than the outer and inner medulla, but tubular
epithelial cells are especially vulnerable to hypoxic injury due to
their high metabolic rate and reliance on aerobic metabolism
(Epstein, 1997). In CKD, a series of factors lead to the develop-
ment of a hypoxic state. The oxygen consumption of remnant
nephrons within the diseased kidney is up to three times the oxygen
requirement of normal nephrons due to the up-regulated meta-
bolic activity of tubular cells (Harris et al., 1988). The capability of
the cardiovascular system to meet this demand is hindered by the
loss of peritubular capillaries associated with tubulointerstitial fi-
brosis (Choi et al., 2000), RAAS mediated vasoconstriction (Nangaku
and Fujita, 2008) and the increased diffusion distance between cap-
illaries and tubular cells created by the expansion of the ECM,
resulting in tissue hypoxia.
Hypoxia acts to drive fibrogenesis through multiple pathways.
Tubular cells exposed to mild hypoxia have been demonstrated to
undergo transition into myofibroblasts (Xie et al., 2001; Zell et al.,
2013) and exposure to severe hypoxia can result in apoptosis (Khan
et al., 1999). Hypoxia also has direct effects on renal fibroblasts, re-
sulting in increased matrix production, decreased matrix turnover
and production of pro-fibrotic mediators (Norman et al., 2000).
Hypoxia may also act as a stimulus for the inflammatory response
via the recruitment of inflammatory cells (Kong et al., 2004).
In cats high urinary vascular endothelial growth factor (VEG-
F), a marker of hypoxia within tissues, has been associated with
shorter survival and progression of azotaemia, suggesting renal
hypoxia is associated with progression in feline CKD (Chakrabarti
et al., 2012b). However another recent study found that urinary
VEG-F was significantly lower in cats with CKD than normal cats,
so the significance of this marker and the role of hypoxia in feline
CKD remains undetermined (Habenicht et al., 2013).
Ageing
The ageing kidney is characterised by a number of progressive
morphological changes, including loss of renal mass, glomerulo-
sclerosis and interstitial fibrosis (Pannarale et al., 2010). The amount
of ECM present within the renal interstitium increases signifi-
cantly with age (Abrass et al., 1995; Thomas et al., 1998), although
this change differs substantially from the interstitial fibrosis of CKD
with respect to the ECM composition. In cats, there is evidence that
tubulointerstitial inflammation begins early in life and that these
histopathological changes increase significantly with age (Lawler
et al., 2006). The mechanisms behind age-related fibrogenesis are
multifactorial and include increased inflammatory cell infiltra-
tion, increased myofibroblast activation, increased susceptibility to
apoptosis and adverse haemodynamic changes in aged kidneys
(Thomas et al., 1998). The expression of several pro-regenerative
growth factors, including epidermal growth factor (EGF) (Chou et al.,
1997) and insulin like growth factor (IGF-1) (Chou et al., 1997), also
decreases with age whilst there is an increase in pro-fibrotic TGF-β
signalling (Ding et al., 2001).
The ageing process compromises the ability of the kidney to heal
after acute or chronic injury, with various alterations contributing
towards perpetuation of the chronic inflammatory response and sub-
sequent fibrosis rather than resolution of the reparative phase
(Pannarale et al., 2010). Studies utilising experimental models of
renal injury have revealed an age dependent decline in the prolif-
erative potential of tubular epithelial cells (Schmitt et al., 2008)
believed to be associated with cellular senescence, the phenome-
nonwhere cells lose the ability to divide or replicate and thus cannot
contribute to active repair. Cellular senescence is associated with
shorter length of telomeres, the structures which protect the chro-
mosome ends from degradation (Bodnar et al., 1998), and is
characterised by morphological changes and altered cellular func-
tion. Markers of cellular senescence have been associated with renal
fibrosis in experimental rodent models of renal disease as well as
in humans (Melk et al., 2009; Braun et al., 2012) and, together with
shortened telomere length, have also recently been linkedwith feline
CKD (Quimby et al., 2013).
Hyperphosphataemia
Whilst elevated plasma phosphate may be a consequence of pro-
gressive loss of renal function, phosphate has been demonstrated
to be associated with progression of renal disease independent of
GFR in human studies (Zoccali et al., 2011), suggesting that phos-
phate might be causally implicated in renal disease progression.
It has long been recognised that increased plasma phosphate is
associated with pathological changes within the kidney, with pub-
lications dating back to 1935 noting dramatic histological changes,
including necrosis of the convoluted tubules, calcification and an
increase in connective tissue, in normal animals fed high phos-
phate diets (Mackay and Oliver, 1935; Craig, 1959; Haut et al., 1980).
Feeding of a phosphate restricted diet to cats with experimentally
induced renal disease has been demonstrated to prevent histologi-
cal damage in comparison with cats fed a high phosphate diet, the
kidneys of which developed calcification, fibrosis and mono-
nuclear cell infiltration (Ross et al., 1982). Initially there was
controversy regarding these findings, as diets low in phosphate are
also intrinsically associated with protein restriction (Laouari et al.,
1982). Subsequent studies have supported the fact that phos-
phate restriction reduces renal injury in experimental models of
disease independent of protein intake (Lumlertgul et al., 1986; Finco
et al., 1992; Koizumi et al., 2002), whereas the benefit of protein
restriction on the progression of CKD is controversial.
Themechanism for the detrimental effect of hyperphosphataemia
on kidney tissue is unknown. The most common explanation for
the deleterious effects of phosphate in these models is phosphate-
induced calcification of the renal parenchyma resulting in an
inflammatory and fibrotic response. There is evidence from human
CKD and experimental models that hyperphosphataemia is asso-
ciatedwith nephrocalcinosis and subsequent functional deterioration
(Gimenez et al., 1987; Cozzolino et al., 2002). However, in the only
published work relating kidney lesions to clinicopathologic vari-
ables in cats with naturally occurring CKD, plasma phosphate was
associated with interstitial fibrosis but was not associated with
tubular mineralisation (Chakrabarti et al., 2013). This suggests that
the association between phosphate and progressive kidney fibro-
sis in cats may not involve parenchymal mineralisation but occurs
via another mechanism.
Several alternative mechanisms have been proposed. In pa-
tients with CKD and other syndromes which cause elevated plasma
phosphate, hyperphosphataemia is associated with vascular
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calcification and stiffness (Kendrick and Chonchol, 2011).
Hyperphosphataemia may also interfere with the function of, and
even directly damage, the microvascular endothelium within the
kidney (Kang et al., 2002; Di Marco et al., 2008; Shuto et al., 2009).
These negative haemodynamic consequences may lead to isch-
aemia and hypoxia, and hence progressive fibrotic change. Phosphate
may have direct effects on epithelial and mesenchymal cells within
the kidney, leading to a pro-fibrotic state. Increased extracellular
phosphate has wide ranging effects on cellular physiology (Camalier
et al., 2013) and has been associated with apoptosis (Ohnishi and
Razzaque, 2010), cellular senescence (Takemura et al., 2011) and
oxidative stress (Kuro-o, 2010). Increasing concentrations of extra-
cellular phosphate have also been demonstrated to increase the
production of ECM and pro-fibrotic molecules by fibroblasts (Beck
et al., 2000; Chen et al., 2012). Alternatively, phosphate may act in-
directly via effects on the RAAS. Increased plasma phosphate may
result in increased ACE expression within the kidney (Eraranta et al.,
2012), and high plasma phosphate was associated with attenua-
tion of the renoprotective effects of ACE inhibition in one human
epidemiological study (Zoccali et al., 2011).
Conclusions
Halting or slowing the insidious progression of renal fibrosis is
an ideal treatment target for preventing deterioration of CKD to end
stage kidney disease, as it is the final convergent process of a variety
of renal pathologies. Several of the mechanisms reviewed in this
article are already targeted in the treatment recommendations for
CKD in cats published by the International Renal Interest Society.1
Cats diagnosed with stage 2 CKD and above with urine protein to
creatinine ratio persistently higher than 0.4 should be treated with
anti-proteinuric measures, which may include dietary protein re-
striction and pharmacological ACE or angiotensin II inhibition. The
IRIS guidelines also include target reference ranges for plasma phos-
phate for cats in difference stages of CKD and a reduction of
phosphate intake via dietary restriction, often in combination with
a dietary phosphate binder, is recommended to maintain plasma
phosphate within these ranges (Table 1). The future promises further
therapeutics targeting the progression of renal fibrosis. A number
of inhibitors of the TGF-β signalling system have been trialled ex-
perimentally and there is ongoing research into pharmacological
manipulation of the kidney’s response to hypoxia. It is hoped that
further elucidation of the role played by these potential media-
tors of injury will lead to novel therapeutic targets, and better clinical
outcomes, in the treatment of feline CKD.
Conflict of interest statement
None of the authors has any financial or personal relationships
that could inappropriately influence or bias the content of the paper.
Acknowledgements
JL is in receipt of a BBSRC CASE studentship co-funded by Novartis
Animal Health but they played no role in the study design, in the
collection, analysis and interpretation of data, or in the manu-
script writing or submission for publication. JE is a member of the
International Renal Interest Society which is sponsored by Novartis
Animal Health.
References
Abbate, M., Zoja, C., Corna, D., Capitanio, M., Bertani, T., Remuzzi, G., 1998. In
progressive nephropathies, overload of tubular cells with filtered proteins
translates glomerular permeability dysfunction into cellular signals of interstitial
inflammation. Journal of the American Society of Nephrology 9, 1213–1224.
Abbate, M., Zoja, C., Rottoli, D., Corna, D., Tomasoni, S., Remuzzi, G., 2002. Proximal
tubular cells promote fibrogenesis by TGF-beta1-mediated induction of
peritubular myofibroblasts. Kidney International 61, 2066–2077.
Abrass, C.K., Adcox, M.J., Raugi, G.J., 1995. Aging-associated changes in renal
extracellular matrix. The American Journal of Pathology 146, 742–752.
Annes, J.P., Munger, J.S., Rifkin, D.B., 2003. Making sense of latent TGFbeta activation.
Journal of Cell Science 116, 217–224.
Arata, S., Ohmi, A., Mizukoshi, F., Baba, K., Ohno, K., Setoguchi, A., Tsujimoto, H., 2005.
Urinary transforming growth factor-beta1 in feline chronic renal failure. The
Journal of Veterinary Medical Science 67, 1253–1255.
Atlas, S.A., 2007. The renin-angiotensin aldosterone system: Pathophysiological role
and pharmacologic inhibition. Journal of Managed Care Pharmacy 13, 9–20.
Bartlett, P.C., Van Buren, J.W., Neterer, M., Zhou, C., 2010. Disease surveillance and
referral bias in the veterinary medical database. Preventive Veterinary Medicine
94, 264–271.
Beck, G.R., Jr., Zerler, B., Moran, E., 2000. Phosphate is a specific signal for induction
of osteopontin gene expression. Proceedings of the National Academy of Sciences
of the United States of America 97, 8352–8357.
Belkin, A.M., 2011. Extracellular TG2: Emerging functions and regulation. The FEBS
Journal 278, 4704–4716.
Benigni, A., Zoja, C., Corna, D., Orisio, S., Longaretti, L., Bertani, T., Remuzzi, G., 1993.
A specific endothelin subtype A receptor antagonist protects against injury in
renal disease progression. Kidney International 44, 440–444.
Bodnar, A.G., Ouellette, M., Frolkis, M., Holt, S.E., Chiu, C.P., Morin, G.B., Harley, C.B.,
Shay, J.W., Lichtsteiner, S., Wright, W.E., 1998. Extension of life-span by
introduction of telomerase into normal human cells. Science 279, 349–352.
Bonventre, J.V., 2003. Dedifferentiation and proliferation of surviving epithelial cells
in acute renal failure. Journal of the American Society of Nephrology 14 (Suppl.
1), S55–S61.
Border, W.A., Noble, N.A., 1993. Cytokines in kidney disease: The role of transforming
growth factor-beta. American Journal of Kidney Diseases 22, 105–113.
Braun, H., Schmidt, B.M.W., Raiss, M., Baisantry, A., Mircea-Constantin, D., Wang, S.J.,
Gross, M.L., Serrano, M., Schmitt, R., Melk, A., 2012. Cellular senescence limits
regenerative capacity and allograft survival. Journal of the American Society of
Nephrology 23, 1467–1473.
Camalier, C.E., Yi, M., Yu, L.R., Hood, B.L., Conrads, K.A., Lee, Y.J., Lin, Y., Garneys, L.M.,
Bouloux, G.F., Young, M.R., et al., 2013. An integrated understanding of the
physiological response to elevated extracellular phosphate. Journal of Cellular
Physiology 228, 1536–1550.
Chakrabarti, S., 2012. Mechanisms of Fibrosis in Feline Chronic Kidney Disease. Royal
Veterinary College, London.
Chakrabarti, S., Syme, H.M., Elliott, J., 2012a. Clinicopathological variables predicting
progression of azotemia in cats with chronic kidney disease. Journal of Veterinary
Internal Medicine 26, 275–281.
Chakrabarti, S., Syme, H.M., Elliott, J., 2012b. Urinary vascular endothelial growth
factor as a prognostic marker in feline chronic kidney disease. Journal of
Veterinary Internal Medicine 26, 1524.
Chakrabarti, S., Syme, H.M., Brown, C.A., Elliott, J., 2013. Histomorphometry of feline
chronic kidney disease and correlation with markers of renal dysfunction.
Veterinary Pathology 50, 147–155.
Chen, Z., Chen, D., McCarthy, T.L., Centrella, M., Zhang, Y., Moeckel, G.W., 2012.
Inorganic phosphate stimulates fibronectin expression in renal fibroblasts. Cellular
Physiology and Biochemistry 30, 151–159.
Choi, Y.J., Chakraborty, S., Nguyen, V., Nguyen, C., Kim, B.K., Shim, S.I., Suki, W.N.,
Truong, L.D., 2000. Peritubular capillary loss is associated with chronic
tubulointerstitial injury in human kidney: Altered expression of vascular
endothelial growth factor. Human Pathology 31, 1491–1497.
Chou, J.S., Reiser, I.W., Porush, J.G., 1997. Aging and urinary excretion of epidermal
growth factor. Annals of Clinical and Laboratory Science 27, 116–122.
Cozzolino, M., Dusso, A.S., Liapis, H., Finch, J., Lu, Y., Burke, S.K., Slatopolsky, E., 2002.
The effects of sevelamer hydrochloride and calcium carbonate on kidney
calcification in uremic rats. Journal of the American Society of Nephrology 13,
2299–2308.
Craig, J.M., 1959. Observations on the kidney after phosphate loading in the rat.
Archives of Pathology 68, 306–315.
Di Marco, G.S., Hausberg, M., Hillebrand, U., Rustemeyer, P., Wittkowski, W., Lang,
D., Pavenstadt, H., 2008. Increased inorganic phosphate induces human
1 See IRIS Guidelines: http://www.iris-kidney.com/guidelines/ (accessed 9 April
2014).
Table 1
Target reference ranges for plasma phosphate in cats with CKD.




23J. Lawson et al./The Veterinary Journal 203 (2015) 18–26
endothelial cell apoptosis in vitro. American Journal of Physiology – Renal
Physiology 294, F1381–F1387.
DiBartola, S.P., Rutgers, H.C., Zack, P.M., Tarr, M.J., 1987. Clinicopathologic findings
associated with chronic renal disease in cats: 74 cases (1973–1984). Journal of
the American Veterinary Medical Association 190, 1196–1202.
Ding, G., Franki, N., Kapasi, A.A., Reddy, K., Gibbons, N., Singhal, P.C., 2001. Tubular
cell senescence and expression of TGF-beta1 and p21(WAF1/CIP1) in
tubulointerstitial fibrosis of aging rats. Experimental and Molecular Pathology
70, 43–53.
Duan, S.B., Liu, F.Y., Luo, J.A., Peng, Y.M., 1999. Assessment of urinary endothelin-1
and nitric oxide levels and their relationship with clinical and pathologic types
in primary glomerulonephritis. Yonsei Medical Journal 40, 425–429.
Ebihara, I., Nakamura, T., Tomino, Y., Koide, H., 1997. Effect of a specific endothelin
receptor A antagonist and an angiotensin-converting enzyme inhibitor on
glomerular mRNA levels for extracellular matrix components, metalloproteinases
(MMP) and a tissue inhibitor of MMP in aminonucleoside nephrosis. Nephrology,
Dialysis, Transplantation 12, 1001–1006.
Eddy, A.A., 1996. Molecular insights into renal interstitial fibrosis. Journal of the
American Society of Nephrology 7, 2495–2508.
Eddy, A.A., Giachelli, C.M., 1995. Renal expression of genes that promote interstitial
inflammation and fibrosis in rats with protein-overload proteinuria. Kidney
International 47, 1546–1557.
Edwards, D.R., Murphy, G., Reynolds, J.J., Whitham, S.E., Docherty, A.J., Angel, P., Heath,
J.K., 1987. Transforming growth factor beta modulates the expression of
collagenase and metalloproteinase inhibitor. The EMBO Journal 6, 1899–1904.
Epstein, F.H., 1997. Oxygen and renal metabolism. Kidney International 51, 381–385.
Eraranta, A., Riutta, A., Fan, M., Koskela, J., Tikkanen, I., Lakkisto, P., Niemela, O.,
Parkkinen, J., Mustonen, J., Porsti, I., 2012. Dietary phosphate binding and loading
alter kidney angiotensin-converting enzyme mRNA and protein content in 5/6
nephrectomized rats. American Journal of Nephrology 35, 401–408.
Evans, R.G., Gardiner, B.S., Smith, D.W., O’Connor, P.M., 2008. Intrarenal oxygenation:
Unique challenges and the biophysical basis of homeostasis. American Journal
of Physiology – Renal Physiology 295, F1259–F1270.
Farris, A.B., Colvin, R.B., 2012. Renal interstitial fibrosis: Mechanisms and evaluation.
Current Opinion in Nephrology and Hypertension 21, 289–300.
Finco, D.R., Brown, S.A., Crowell, W.A., Duncan, R.J., Barsanti, J.A., Bennett, S.E., 1992.
Effects of dietary phosphorus and protein in dogs with chronic renal failure.
American Journal of Veterinary Research 53, 2264–2271.
Fukuda, K., Yoshitomi, K., Yanagida, T., Tokumoto, M., Hirakata, H., 2001. Quantification
of TGF-beta1 mRNA along rat nephron in obstructive nephropathy. American
Journal of Physiology – Renal Physiology 281, F513–F521.
Garber, S.L., Mirochnik, Y., Desai, S.S., Arruda, J.A., Dunea, G., 1998. Angiotensin-
converting enzyme inhibition reduces the effect of bromoethylamine-induced
papillary necrosis and renal fibrosis. Journal of the American Society of
Nephrology 9, 1052–1059.
Gentle, M.E., Shi, S., Daehn, I., Zhang, T., Qi, H., Yu, L., D’Agati, V.D., Schlondorff, D.O.,
Bottinger, E.P., 2013. Epithelial cell TGFbeta signaling induces acute tubular injury
and interstitial inflammation. Journal of the American Society of Nephrology 24,
787–799.
Gimenez, L.F., Solez, K., Walker, W.G., 1987. Relation between renal calcium content
and renal impairment in 246 human renal biopsies. Kidney International 31,
93–99.
Grotendorst, G.R., 1997. Connective tissue growth factor: A mediator of TGF-beta
action on fibroblasts. Cytokine and Growth Factor Reviews 8, 171–179.
Habenicht, L.M., Webb, T.L., Clauss, L.A., Dow, S.W., Quimby, J.M., 2013. Urinary
cytokine levels in apparently healthy cats and cats with chronic kidney disease.
Journal of Feline Medicine and Surgery 15, 99–104.
Han, K.H., Kang, Y.S., Han, S.Y., Jee, Y.H., Lee, M.H., Han, J.Y., Kim, H.K., Kim, Y.S., Cha,
D.R., 2006. Spironolactone ameliorates renal injury and connective tissue growth
factor expression in type II diabetic rats. Kidney International 70, 111–120.
Harris, D.C., Chan, L., Schrier, R.W., 1988. Remnant kidney hypermetabolism and
progression of chronic renal failure. The American Journal of Physiology 254,
F267–F276.
Haut, L.L., Alfrey, A.C., Guggenheim, S., Buddington, B., Schrier, N., 1980. Renal toxicity
of phosphate in rats. Kidney International 17, 722–731.
He, J., Xu, Y., Koya, D., Kanasaki, K., 2013. Role of the endothelial-to-mesenchymal
transition in renal fibrosis of chronic kidney disease. Clinical and Experimental
Nephrology 17, 488–497.
Hocher, B., Thone-Reineke, C., Rohmeiss, P., Schmager, F., Slowinski, T., Burst, V.,
Siegmund, F., Quertermous, T., Bauer, C., Neumayer, H.H., et al., 1997. Endothelin-1
transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts
but not hypertension. The Journal of Clinical Investigation 99, 1380–1389.
Hostetter, T.H., Olson, J.L., Rennke, H.G., Venkatachalam, M.A., Brenner, B.M., 1981.
Hyperfiltration in remnant nephrons: A potentially adverse response to renal
ablation. The American Journal of Physiology 241, F85–F93.
Huang, L., Haylor, J.L., Hau, Z., Jones, R.A., Vickers, M.E., Wagner, B., Griffin, M., Saint,
R.E., Coutts, I.G., El Nahas, A.M., et al., 2009. Transglutaminase inhibition
ameliorates experimental diabetic nephropathy. Kidney International 76,
383–394.
Huang, Y., Wongamorntham, S., Kasting, J., McQuillan, D., Owens, R.T., Yu, L., Noble,
N.A., Border, W., 2006. Renin increases mesangial cell transforming growth
factor-beta1 and matrix proteins through receptor-mediated, angiotensin
II-independent mechanisms. Kidney International 69, 105–113.
Hughes, A.K., Stricklett, P.K., Padilla, E., Kohan, D.E., 1996. Effect of reactive oxygen
species on endothelin-1 production by human mesangial cells. Kidney
International 49, 181–189.
Hughes, K.L., Slater, M.R., Geller, S., Burkholder, W.J., Fitzgerald, C., 2002. Diet and
lifestyle variables as risk factors for chronic renal failure in pet cats. Preventive
Veterinary Medicine 55, 1–15.
Iismaa, S.E., Mearns, B.M., Lorand, L., Graham, R.M., 2009. Transglutaminases and
disease: Lessons from genetically engineered mouse models and inherited
disorders. Physiological Reviews 89, 991–1023.
Ishidoya, S., Morrissey, J., McCracken, R., Klahr, S., 1996. Delayed treatment with
enalapril halts tubulointerstitial fibrosis in rats with obstructive nephropathy.
Kidney International 49, 1110–1119.
Jabs, A., Moncada, G.A., Nichols, C.E., Waller, E.K., Wilcox, J.N., 2005. Peripheral blood
mononuclear cells acquire myofibroblast characteristics in granulation tissue.
Journal of Vascular Research 42, 174–180.
Jepson, R.E., Brodbelt, D., Vallance, C., Syme, H.M., Elliott, J., 2009. Evaluation of
predictors of the development of azotemia in cats. Journal of Veterinary Internal
Medicine 23, 806–813.
Johnson, T.S., 2003. Tissue transglutaminase and the progression of human renal
scarring. Journal of the American Society of Nephrology 14, 2052–2062.
Johnson, T.S., Skill, N.J., El Nahas, A.M., Oldroyd, S.D., Thomas, G.L., Douthwaite, J.A.,
Haylor, J.L., Griffin, M., 1999. Transglutaminase transcription and antigen
translocation in experimental renal scarring. Journal of the American Society of
Nephrology 10, 2146–2157.
Johnson, T.S., Fisher, M., Haylor, J.L., Hau, Z., Skill, N.J., Jones, R., Saint, R., Coutts,
I., Vickers, M.E., El Nahas, A.M., et al., 2007. Transglutaminase inhibition reduces
fibrosis and preserves function in experimental chronic kidney disease. Journal
of the American Society of Nephrology 18, 3078–3088.
Juknevicius, I., Segal, Y., Kren, S., Lee, R., Hostetter, T.H., 2004. Effect of aldosterone
on renal transforming growth factor-beta. American Journal of Physiology – Renal
Physiology 286, F1059–F1062.
Kang, D.H., Kanellis, J., Hugo, C., Truong, L., Anderson, S., Kerjaschki, D., Schreiner,
G.F., Johnson, R.J., 2002. Role of the microvascular endothelium in progressive
renal disease. Journal of the American Society of Nephrology 13, 806–816.
Kendrick, J., Chonchol, M., 2011. The role of phosphorus in the development and
progression of vascular calcification. American Journal of Kidney Diseases 58,
826–834.
Khan, S., Cleveland, R.P., Koch, C.J., Schelling, J.R., 1999. Hypoxia induces renal tubular
epithelial cell apoptosis in chronic renal disease. Laboratory Investigation 79,
1089–1099.
Kim, D.S., Kim, B., Tahk, H., Kim, D.H., Ahn, E.R., Choi, C., Jeon, Y., Park, S.Y., Lee, H.,
Oh, S.H., et al., 2010. Transglutaminase 2 gene ablation protects against renal
ischemic injury by blocking constant NF-kappaB activation. Biochemical and
Biophysical Research Communications 403, 479–484.
Kim, M.K., Maeng, Y.I., Sung, W.J., Oh, H.K., Park, J.B., Yoon, G.S., Cho, C.H., Park, K.K.,
2013. The differential expression of TGF-beta1, ILK and wnt signaling inducing
epithelial to mesenchymal transition in human renal fibrogenesis: An
immunohistochemical study. International Journal of Clinical and Experimental
Pathology 6, 1747–1758.
King, J.N., Gunn-Moore, D.A., Tasker, S., Gleadhill, A., Strehlau, G., Benazepril in Renal
Insufficiency in Cats Study Group, 2006. Tolerability and efficacy of benazepril
in cats with chronic kidney disease. Journal of Veterinary Internal Medicine 20,
1054–1064.
Ko, G.J., Boo, C.S., Jo, S.K., Cho, W.Y., Kim, H.K., 2008. Macrophages contribute to the
development of renal fibrosis following ischaemia/reperfusion-induced acute
kidney injury. Nephrology, Dialysis, Transplantation 23, 842–852.
Kobori, H., Nangaku, M., Navar, L.G., Nishiyama, A., 2007. The intrarenal renin-
angiotensin system: From physiology to the pathobiology of hypertension and
kidney disease. Pharmacological Reviews 59, 251–287.
Koesters, R., Kaissling, B., Lehir, M., Picard, N., Theilig, F., Gebhardt, R., Glick, A.B.,
Hahnel, B., Hosser, H., Grone, H.J., et al., 2010. Tubular overexpression of
transforming growth factor-beta1 induces autophagy and fibrosis but not
mesenchymal transition of renal epithelial cells. The American Journal of
Pathology 177, 632–643.
Kohno, M., Horio, T., Ikeda, M., Yokokawa, K., Fukui, T., Yasunari, K., Kurihara, N.,
Takeda, T., 1992. Angiotensin II stimulates endothelin-1 secretion in cultured rat
mesangial cells. Kidney International 42, 860–866.
Koizumi, T., Murakami, K., Nakayama, H., Kuwahara, T., Yoshinari, O., 2002. Role of
dietary phosphorus in the progression of renal failure. Biochemical and
Biophysical Research Communications 295, 917–921.
Kong, T., Eltzschig, H.K., Karhausen, J., Colgan, S.P., Shelley, C.S., 2004. Leukocyte
adhesion during hypoxia is mediated by HIF-1-dependent induction of beta2
integrin gene expression. Proceedings of the National Academy of Sciences of
the United States of America 101, 10440–10445.
Krag, S., Danielsen, C.C., Carmeliet, P., Nyengaard, J., Wogensen, L., 2005. Plasminogen
activator inhibitor-1 gene deficiency attenuates TGF-beta1-induced kidney
disease. Kidney International 68, 2651–2666.
Kuro-o, M., 2010. A potential link between phosphate and aging – Lessons from
Klotho-deficient mice. Mechanisms of Ageing and Development 131, 270–
275.
Laouari, D., Kleinknecht, C., Cournot-Witmer, G., Habib, R., Mounier, F., Broyer, M.,
1982. Beneficial effect of low phosphorus diet in uraemic rats: A reappraisal.
Clinical Science 63, 539–548.
Lappin, M.R., Basaraba, R.J., Jensen, W.A., 2006. Interstitial nephritis in cats inoculated
with Crandell Rees feline kidney cell lysates. Journal of Feline Medicine and
Surgery 8, 353–356.
Largo, R., Gomez-Garre, D., Soto, K., Marron, B., Blanco, J., Gazapo, R.M., Plaza,
J.J., Egido, J., 1999. Angiotensin-converting enzyme is upregulated in the proximal
tubules of rats with intense proteinuria. Hypertension 33, 732–739.
24 J. Lawson et al./The Veterinary Journal 203 (2015) 18–26
Lawler, D.F., Evans, R.H., Chase, K., Ellersieck, M., Li, Q., Larson, B.T., Satyaraj, E.,
Heininger, K., 2006. The aging feline kidney: A model mortality antagonist?
Journal of Feline Medicine and Surgery 8, 363–371.
Lebel, M., Rodrigue, M.E., Agharazii, M., Lariviere, R., 2006. Antihypertensive and renal
protective effects of renin-angiotensin system blockade in uremic rats treated
with erythropoietin. American Journal of Hypertension 19, 1286–1292.
Lebleu, V.S., Taduri, G., O’Connell, J., Teng, Y., Cooke, V.G., Woda, C., Sugimoto, H.,
Kalluri, R., 2013. Origin and function of myofibroblasts in kidney fibrosis. Nature
Medicine 19, 1047–1053.
Lee, S., Huen, S., Nishio, H., Nishio, S., Lee, H.K., Choi, B.S., Ruhrberg, C., Cantley, L.G.,
2011. Distinct macrophage phenotypes contribute to kidney injury and repair.
Journal of the American Society of Nephrology 22, 317–326.
Liu, Y., 2006. Renal fibrosis: New insights into the pathogenesis and therapeutics.
Kidney International 69, 213–217.
Lulich, J.P., Osborne, C.A., O’Brien, T.D., Polzin, D.J., 1992. Feline renal failure: Questions,
answers, questions. Compendium on Continuing Education for the Practising
Veterinarian 14, 127–152.
Lumlertgul, D., Burke, T.J., Gillum, D.M., Alfrey, A.C., Harris, D.C., Hammond, W.S.,
Schrier, R.W., 1986. Phosphate depletion arrests progression of chronic renal
failure independent of protein intake. Kidney International 29, 658–666.
Mackay, E.M., Oliver, J., 1935. Renal damage following the ingestion of a diet
containing an excess of inorganic phosphate. The Journal of Experimental
Medicine 61, 319–334.
Manotham, K., Tanaka, T., Matsumoto, M., Ohse, T., Miyata, T., Inagi, R., Kurokawa,
K., Fujita, T., Nangaku, M., 2004. Evidence of tubular hypoxia in the early phase
in the remnant kidney model. Journal of the American Society of Nephrology
15, 1277–1288.
Maschio, G., Alberti, D., Janin, G., Locatelli, F., Mann, J.F., Motolese, M., Ponticelli, C.,
Ritz, E., Zucchelli, P., 1996. Effect of the angiotensin-converting-enzyme inhibitor
benazepril on the progression of chronic renal insufficiency. The Angiotensin-
Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.
The New England Journal of Medicine 334, 939–945.
Melk, A., Schmidt, B.M.W., Braun, H., Vongwiwatana, A., Urmson, J., Zhu, L.F., Rayner,
D., Halloran, P.F., 2009. Effects of donor age and cell senescence on kidney allograft
survival. American Journal of Transplantation 9, 114–123.
Mimura, I., Nangaku, M., 2010. The suffocating kidney: Tubulointerstitial hypoxia in
end-stage renal disease. Nature Reviews. Nephrology 6, 667–678.
Minkus, G., Reusch, C., Hörauf, A., Breuer, W., Darbès, J., Kraft, W., Hermanns, W.,
1994. Evaluation of renal biopsies in cats and dogs – Histopathology in
comparison with clinical data. Journal of Small Animal Practice 35, 465–472.
Mitani, S., Yabuki, A., Taniguchi, K., Yamato, O., 2013. Association between the
intrarenal renin-angiotensin system and renal injury in chronic kidney disease
of dogs and cats. The Journal of Veterinary Medical Science 75, 127–133.
Mizuno, S., Horikawa, Y., Okamoto, M., Kurosawa, T., 1998. Preventive effect of ACE
inhibitor on interstitial myofibroblast formation and matrix deposition in a
nephrotic model. Renal Failure 20, 481–491.
Mizutani, H., Koyama, H., Watanabe, T., Kitagawa, H., Nakano, M., Kajiwara, K., King,
J.N., 2006. Evaluation of the clinical efficacy of benazepril in the treatment of
chronic renal insufficiency in cats. Journal of Veterinary Internal Medicine 20,
1074–1079.
Moll, S., Ebeling, M., Weibel, F., Farina, A., Araujo Del Rosario, A., Hoflack, J.C.,
Pomposiello, S., Prunotto, M., 2013. Epithelial cells as active player in fibrosis:
Findings from an in vitro model. PLoS ONE 8, e56575.
Nakajima, H., Takenaka, M., Kaimori, J.Y., Nagasawa, Y., Kosugi, A., Kawamoto, S., Imai,
E., Hori, M., Okubo, K., 2002. Gene expression profile of renal proximal tubules
regulated by proteinuria. Kidney International 61, 1577–1587.
Nakamura, T., Ushiyama, C., Shimada, N., Hayashi, K., Ebihara, I., Koide, H., 2000.
Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary
endothelin-1 and albumin excretion in diabetes patients. Journal of Diabetes and
Its Complications 14, 250–254.
Nangaku, M., Fujita, T., 2008. Activation of the renin-angiotensin system and chronic
hypoxia of the kidney. Hypertension Research 31, 175–184.
Nath, K.A., 1992. Tubulointerstitial changes as a major determinant in the progression
of renal damage. American Journal of Kidney Diseases 20, 1–17.
Nikolic-Paterson, D.J., 2010. CD4+ T cells: A potential player in renal fibrosis. Kidney
International 78, 333–335.
Norman, J.T., Clark, I.M., Garcia, P.L., 2000. Hypoxia promotes fibrogenesis in human
renal fibroblasts. Kidney International 58, 2351–2366.
Ohnishi, M., Razzaque, M.S., 2010. Dietary and genetic evidence for phosphate toxicity
accelerating mammalian aging. FASEB Journal 24, 3562–3571.
Ong, A.C., Newby, L.J., Dashwood, M.R., 2003. Expression and cellular localisation of
renal endothelin-1 and endothelin receptor subtypes in autosomal-dominant
polycystic kidney disease. Nephron. Experimental Nephrology 93, e80.
Orphanides, C., Fine, L.G., Norman, J.T., 1997. Hypoxia stimulates proximal tubular
cell matrix production via a TGF-beta1-independent mechanism. Kidney
International 52, 637–647.
Pannarale, G., Carbone, R., Del Mastro, G., Gallo, C., Gattullo, V., Natalicchio, L., Navarra,
A., Tedesco, A., 2010. The aging kidney: Structural changes. Journal of Nephrology
23 (Suppl. 15), S37–S40.
Prunotto, M., Ghiggeri, G., Bruschi, M., Gabbiani, G., Lescuyer, P., Hocher, B.,
Chaykovska, L., Berrera, M., Moll, S., 2011. Renal fibrosis and proteomics: Current
knowledge and still key open questions for proteomic investigation. Journal of
Proteomics 74, 1855–1870.
Prunotto, M., Budd, D.C., Gabbiani, G., Meier, M., Formentini, I., Hartmann, G.,
Pomposiello, S., Moll, S., 2012. Epithelial-mesenchymal crosstalk alteration in
kidney fibrosis. The Journal of Pathology 228, 131–147.
Qi, W., Chen, X., Poronnik, P., Pollock, C.A., 2006. The renal cortical fibroblast in renal
tubulointerstitial fibrosis. The International Journal of Biochemistry and Cell
Biology 38, 1–5.
Quimby, J.M., Maranon, D.G., Battaglia, C.L., McLeland, S.M., Brock, W.T., Bailey, S.M.,
2013. Feline chronic kidney disease is associated with shortened telomeres and
increased cellular senescence. American Journal of Physiology - Renal Physiology
305, F295–F303.
Reynolds, B.S., Lefebvre, H.P., 2013. Feline CKD: Pathophysiology and risk factors –
What do we know? Journal of Feline Medicine and Surgery 15 (Suppl. 1), 3–14.
Risdon, R.A., Sloper, J.C., DeWardener, H.E., 1968. Relationship between renal function
and histological changes found in renal-biopsy specimens from patients with
persistent glomerular nephritis. Lancet 2, 363–366.
Rodriguez-Iturbe, B., Garcia Garcia, G., 2010. The role of tubulointerstitial
inflammation in the progression of chronic renal failure. Nephron. Clinical Practice
116, c81–c88.
Rodriguez-Iturbe, B., Pons, H., Herrera-Acosta, J., Johnson, R.J., 2001. Role of
immunocompetent cells in nonimmune renal diseases. Kidney International 59,
1626–1640.
Rohatgi, R., Flores, D., 2010. Intratubular hydrodynamic forces influence
tubulointerstitial fibrosis in the kidney. Current Opinion in Nephrology and
Hypertension 19, 65–71.
Romero, F., Rodriguez-Iturbe, B., Parra, G., Gonzalez, L., Herrera-Acosta, J., Tapia, E.,
1999. Mycophenolate mofetil prevents the progressive renal failure induced by
5/6 renal ablation in rats. Kidney International 55, 945–955.
Ross, L.A., Finco, D.R., Crowell, W.A., 1982. Effect of dietary phosphorus restriction
on the kidneys of cats with reduced renal mass. American Journal of Veterinary
Research 43, 1023–1026.
Roubert, P., Gillard-Roubert, V., Pourmarin, L., Cornet, S., Guilmard, C., Plas, P., Pirotzky,
E., Chabrier, P.E., Braquet, P., 1994. Endothelin receptor subtypes A and B are
up-regulated in an experimental model of acute renal failure. Molecular
Pharmacology 45, 182–188.
Ruster, C., Wolf, G., 2011. Angiotensin II as a morphogenic cytokine stimulating renal
fibrogenesis. Journal of the American Society of Nephrology 22, 1189–1199.
Sánchez-Lara, A.C., Elliott, J., Syme, H.M., Brown, C., Haylor, J.L., 2013. Feline Chronic
Kidney Disease is Associated with Upregulation of Transglutaminase, a Cross-
Linking Enzyme. In: ECVIM-CA Congress, Liverpool, p. 719.
Sato, M., Muragaki, Y., Saika, S., Roberts, A.B., Ooshima, A., 2003. Targeted disruption
of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis
induced by unilateral ureteral obstruction. The Journal of Clinical Investigation
112, 1486–1494.
Sawashima, K., Mizuno, S., Mizuno-Horikawa, Y., Shimada, A., Kudo, T., Kurosawa,
T., 2000. Expression of alpha-smooth muscle actin and fibronectin in
tubulointerstitial lesions of cats with chronic renal failure. American Journal of
Veterinary Research 61, 1080–1086.
Schmitt, R., Marlier, A., Cantley, L.G., 2008. Zag expression during aging suppresses
proliferation after kidney injury. Journal of the American Society of Nephrology
19, 2375–2383.
Schnermann, J.B., Zhu, X.L., Shu, X., Yang, T., Huang, Y.G., Kretzler, M., Briggs, J.P., 1996.
Regulation of endothelin production and secretion in cultured collecting duct
cells by endogenous transforming growth factor-beta. Endocrinology 137,
5000–5008.
Serini, G., Bochaton-Piallat, M.L., Ropraz, P., Geinoz, A., Borsi, L., Zardi, L., Gabbiani,
G., 1998. The fibronectin domain ED-A is crucial for myofibroblastic phenotype
induction by transforming growth factor-beta1. The Journal of Cell Biology 142,
873–881.
Shin, D.M., Jeon, J.H., Kim, C.W., Cho, S.Y., Lee, H.J., Jang, G.Y., Jeong, E.M., Lee, D.S.,
Kang, J.H., Melino, G., et al., 2008. TGFbetamediates activation of transglutaminase
2 in response to oxidative stress that leads to protein aggregation. The FASEB
Journal 22, 2498–2507.
Shuto, E., Taketani, Y., Tanaka, R., Harada, N., Isshiki, M., Sato, M., Nashiki, K., Amo,
K., Yamamoto, H., Higashi, Y., et al., 2009. Dietary phosphorus acutely impairs
endothelial function. Journal of the American Society of Nephrology 20, 1504–
1512.
Shweke, N., Boulos, N., Jouanneau, C., Vandermeersch, S., Melino, G., Dussaule, J.C.,
Chatziantoniou, C., Ronco, P., Boffa, J.J., 2008. Tissue transglutaminase contributes
to interstitial renal fibrosis by favoring accumulation of fibrillar collagen through
TGF-beta activation and cell infiltration. The American Journal of Pathology 173,
631–642.
Siragy, H.M., Carey, R.M., 2010. Role of the intrarenal renin-angiotensin-aldosterone
system in chronic kidney disease. American Journal of Nephrology 31, 541–
550.
Strutz, F., Zeisberg, M., 2006. Renal fibroblasts and myofibroblasts in chronic kidney
disease. Journal of the American Society of Nephrology 17, 2992–2998.
Sun, Y., Zhang, J., Zhang, J.Q., Ramires, F.J., 2000. Local angiotensin II and transforming
growth factor-beta1 in renal fibrosis of rats. Hypertension 35, 1078–1084.
Syme, H.M., Markwell, P.J., Pfeiffer, D., Elliott, J., 2006. Survival of cats with naturally
occurring chronic renal failure is related to severity of proteinuria. Journal of
Veterinary Internal Medicine 20, 528–535.
Takemura, A., Iijima, K., Ota, H., Son, B.K., Ito, Y., Ogawa, S., Eto, M., Akishita, M., Ouchi,
Y., 2011. Sirtuin 1 retards hyperphosphatemia-induced calcification of vascular
smooth muscle cells. Arteriosclerosis, Thrombosis, and Vascular Biology 31,
2054–2062.
Tamada, S., Nakatani, T., Asai, T., Tashiro, K., Komiya, T., Sumi, T., Okamura, M., Kim,
S., Iwao, H., Kishimoto, T., et al., 2003. Inhibition of nuclear factor-kappaB
activation by pyrrolidine dithiocarbamate prevents chronic FK506 nephropathy.
Kidney International 63, 306–314.
25J. Lawson et al./The Veterinary Journal 203 (2015) 18–26
Tapmeier, T.T., Fearn, A., Brown, K., Chowdhury, P., Sacks, S.H., Sheerin, N.S., Wong,
W., 2010. Pivotal role of CD4+ T cells in renal fibrosis following ureteric
obstruction. Kidney International 78, 351–362.
Taugner, F., Baatz, G., Nobiling, R., 1996. The renin-angiotensin system in cats with
chronic renal failure. Journal of Comparative Pathology 115, 239–252.
Tejera, N., Gomez-Garre, D., Lazaro, A., Gallego-Delgado, J., Alonso, C., Blanco, J., Ortiz,
A., Egido, J., 2004. Persistent proteinuria up-regulates angiotensin II type 2
receptor and induces apoptosis in proximal tubular cells. The American Journal
of Pathology 164, 1817–1826.
Thomas, S.E., Anderson, S., Gordon, K.L., Oyama, T.T., Shankland, S.J., Johnson, R.J.,
1998. Tubulointerstitial disease in aging: Evidence for underlying peritubular
capillary damage, a potential role for renal ischemia. Journal of the American
Society of Nephrology 9, 231–242.
Toback, F.G., 1992. Regeneration after acute tubular necrosis. Kidney International
41, 226–246.
Turan, T., van Harten, J.G., de Water, R., Tuncay, O.L., Kok, D.J., 2003. Is enalapril
adequate for the prevention of renal tissue damage caused by unilateral ureteral
obstruction and/or hyperoxaluria? Urological Research 31, 212–217.
Uchide, T., Saida, K., 2006. Primary structure of cat preproendothelin-2 and cat renal
mRNA expression of preproendothelin-1 and preproendothelin-2 in naturally
occurring renal failure. Experimental Biology and Medicine 231, 997–1000.
Vielhauer, V., Berning, E., Eis, V., Kretzler, M., Segerer, S., Strutz, F., Horuk, R., Grone,
H.J., Schlondorff, D., Anders, H.J., 2004. CCR1 blockade reduces interstitial
inflammation and fibrosis in mice with glomerulosclerosis and nephrotic
syndrome. Kidney International 66, 2264–2278.
Vlachojannis, J.G., Tsakas, S., Petropoulou, C., Goumenos, D.S., Alexandri, S., 2002.
Endothelin-1 in the kidney and urine of patients with glomerular disease and
proteinuria. Clinical Nephrology 58, 337–343.
Vleming, L.J., Baelde, J.J., Westendorp, R.G., Daha, M.R., van Es, L.A., Bruijn, J.A., 1995.
Progression of chronic renal disease in humans is associated with the deposition
of basement membrane components and decorin in the interstitial extracellular
matrix. Clinical Nephrology 44, 211–219.
Wang, W., Koka, V., Lan, H.Y., 2005. Transforming growth factor-beta and Smad
signalling in kidney diseases. Nephrology 10, 48–56.
Watanabe, T., Mishina, M., 2007. Effects of benazepril hydrochloride in cats with
experimentally induced or spontaneously occurring chronic renal failure. The
Journal of Veterinary Medical Science/the Japanese Society of Veterinary Science
69, 1015–1023.
Wolf, G., 2006. Renal injury due to renin-angiotensin-aldosterone system activation
of the transforming growth factor-beta pathway. Kidney International 70,
1914–1919.
Wolf, G., Wenzel, U., Burns, K.D., Harris, R.C., Stahl, R.A., Thaiss, F., 2002. Angiotensin
II activates nuclear transcription factor-kappaB through AT1 and AT2 receptors.
Kidney International 61, 1986–1995.
Wu, C.F., Chiang, W.C., Lai, C.F., Chang, F.C., Chen, Y.T., Chou, Y.H., Wu, T.H., Linn, G.R.,
Ling, H., Wu, K.D., et al., 2013. Transforming growth factor beta-1 stimulates
profibrotic epithelial signaling to activate pericyte-myofibroblast transition
in obstructive kidney fibrosis. The American Journal of Pathology 182, 118–
131.
Wynn, T.A., 2010. Fibrosis under arrest. Nature Medicine 16, 523–525.
Xie, Y., Sakatsume, M., Nishi, S., Narita, I., Arakawa, M., Gejyo, F., 2001. Expression,
roles, receptors, and regulation of osteopontin in the kidney. Kidney International
60, 1645–1657.
Yabuki, A., Mitani, S., Fujiki, M., Misumi, K., Endo, Y., Miyoshi, N., Yamato, O., 2010.
Comparative study of chronic kidney disease in dogs and cats: Induction of
myofibroblasts. Research in Veterinary Science 88, 294–299.
Yokoi, H., Sugawara, A., Mukoyama, M., Mori, K., Makino, H., Suganami, T., Nagae,
T., Yahata, K., Fujinaga, Y., Tanaka, I., et al., 2001. Role of connective tissue growth
factor in profibrotic action of transforming growth factor-beta: A potential target
for preventing renal fibrosis. American Journal of Kidney Diseases 38, S134–
S138.
Zell, S., Schmitt, R., Witting, S., Kreipe, H.H., Hussein, K., Becker, J.U., 2013.
Hypoxia induces mesenchymal gene expression in renal tubular epithelial
cells: An in vitro model of kidney transplant fibrosis. Nephron Extra 3, 50–
58.
Zoccali, C., Ruggenenti, P., Perna, A., Leonardis, D., Tripepi, R., Tripepi, G., Mallamaci,
F., Remuzzi, G., Group, R.S., 2011. Phosphate may promote CKD progression and
attenuate renoprotective effect of ACE inhibition. Journal of the American Society
of Nephrology 22, 1923–1930.
Zoja, C., Benigni, A., Remuzzi, G., 1999. Protein overload activates proximal tubular
cells to release vasoactive and inflammatorymediators. Experimental Nephrology
7, 420–428.
26 J. Lawson et al./The Veterinary Journal 203 (2015) 18–26
